Regeneron shares fall after FDA rejects high-dose eye disease treatment
A view of the Regeneron Pharmaceuticals headquarters in Tarrytown, New York. Lev Radin | LightRocket | Getty Images Shares of Regeneron fell nearly 9% Tuesday after the U.S.…
Read more Regeneron shares fall after FDA rejects high-dose eye disease treatment